장흥문 교수
#췌담도암
|
학력
2000 .03 ~ 2002 .02강원대학교(춘천) 의학 석사
1984 .03 ~ 1990 .02서울대학교 의학 학사
1984 .03 ~ 1990 .02서울대학교 의학 학사
경력
2011 .04 ~ 현재울산의대 서울아산병원 종양내과 교수
2006 .04 ~ 2011 .03울산의대 서울아산병원 종양내과 부교수
1999 .03 ~ 2001 .02한림대의대 조교수
1998 .05 ~ 1999 .02서울대병원 전임의
1991 .03 ~ 1995 .02서울대병원 전공의
1990 .03 ~ 1991 .02서울대병원 인턴
2006 .04 ~ 2011 .03울산의대 서울아산병원 종양내과 부교수
1999 .03 ~ 2001 .02한림대의대 조교수
1998 .05 ~ 1999 .02서울대병원 전임의
1991 .03 ~ 1995 .02서울대병원 전공의
1990 .03 ~ 1991 .02서울대병원 인턴
논문
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.
Bilateral lung metastasectomy in carcinoma of the ampulla of Vater.
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin.
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma:
Potentially Improved Efficacy with Oxaliplatin-containing Regimen.
Preoperative chemoradiotherapy followed by local excision in clinical T2N0 rectal cancer.
Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer.
Heterotopic pancreas of the jejunum: associations between CT and pathology features.
Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
Postoperative radiotherapy for gallbladder cancer.
Significant symptom relief with hepatic artery embolization in a VIPoma with liver metastases : A case report
A UGT1A1 *28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity.
Bilateral lung metastasectomy in carcinoma of the ampulla of Vater.
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin.
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma:
Potentially Improved Efficacy with Oxaliplatin-containing Regimen.
Preoperative chemoradiotherapy followed by local excision in clinical T2N0 rectal cancer.
Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer.
Heterotopic pancreas of the jejunum: associations between CT and pathology features.
Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
Postoperative radiotherapy for gallbladder cancer.
Significant symptom relief with hepatic artery embolization in a VIPoma with liver metastases : A case report
A UGT1A1 *28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity.
저서
암에 대한 모든 것 (가림건강신서 54)
위장관 간질종양 -환자를 위한 치료지침서
위장관 간질종양 -환자를 위한 치료지침서
보도자료
보도자료 내용이 없습니다.
포스팅
Evaluation of genetic mutations and copy number alterations in biliary tract cancer using targeted exome sequencing
Phase 2 study of triplet chemotherapy with oxaliplatin, irinotecan and S-1 (OIS) as first-line treatment in patients with advanced biliary tract cancer (BTC)
Prognostic implications of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin
Prognostic implications of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma treated with first-line gemcitabine / cisplatin
# 357 Clinical Benefit of Maintenance Therapy for Patients with Advanced Biliary Tract Cancer without
Progression on First-Line Gemcitabine plus Cisplatin
Efficacy and Safety of Targeted agents for Treatment of Gastroenteropancreatic (GEP) Neuroendocrine tumor (NET): Single Center Experience
Efficacy of Chemotherapy in Patients with Pancreatic Acinar Cell Carcinoma
Clinical outcomes of patients with pancreatic neuroendocrine tumors treated with targeted agents: single center experience
Gamma Knife Surgery (GKS) Alone versus GKS Followed by Whole Brain Radiotherapy (WBRT) as the Initial Treatment of Brain Metastasis
Phase 2 study of triplet chemotherapy with oxaliplatin, irinotecan and S-1 (OIS) as first-line treatment in patients with advanced biliary tract cancer (BTC)
Prognostic implications of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin
Prognostic implications of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma treated with first-line gemcitabine / cisplatin
# 357 Clinical Benefit of Maintenance Therapy for Patients with Advanced Biliary Tract Cancer without
Progression on First-Line Gemcitabine plus Cisplatin
Efficacy and Safety of Targeted agents for Treatment of Gastroenteropancreatic (GEP) Neuroendocrine tumor (NET): Single Center Experience
Efficacy of Chemotherapy in Patients with Pancreatic Acinar Cell Carcinoma
Clinical outcomes of patients with pancreatic neuroendocrine tumors treated with targeted agents: single center experience
Gamma Knife Surgery (GKS) Alone versus GKS Followed by Whole Brain Radiotherapy (WBRT) as the Initial Treatment of Brain Metastasis
영상자료
영상자료 내용이 없습니다.
발표자료
Surgical resection after imatinib treatment in patients with metastatic or unresectable gastrointestinal stromal tumors
Cetuximab plus FOLFIRI for irinotecan-refractory metastatic colorectal cancer: A retrospective study
Phase I/II Study of Combination Chemotherapy with S-1 and Cisplatin in Patients with Previously Untreated Metastatic or Recurrent Advanced Gastric Cancer (AGC)
Salvage Chemotherapy with Irinotecan, 5-fluorouracil and Leucovorin in Patients with Advanced Gastric Cancer
No Relationship between C-kit Mutation and Response to Imatinib in Korean Patients with Metastatic Gastrointestinal Stromal Tumor
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach:Report of Three Cases
Phase I/II study of combination chemotherapy with S-1 and cisplatin in patients with previously untreated metastatic or recurrent gastric cancer
Clinical Outcome in Gastrointestinal Stromal Tumor Patients who Interrupted Imatinib after Achieving Stable Disease or Better Response
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin in patients with advanced gastric cancer
No relationship between c-kit mutation and response to imatinib in Korean patients with metastatic gastrointestinal stromal tumor
Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer
Efficacy and safery study of epirubicn and etoposide combination chemotherapy in advanced hepatocellular carcinoma
Efficacy and Safety Study of Epirubicin and Etoposide Combination Chemotherapy in Advanced Hepatocellular Carcinoma
Improved survival of metastatic GIST patients in post-imatinib era compared to those in pre-imatinib era
Cetuximab plus FOLFIRI for irinotecan-refractory metastatic colorectal cancer: A retrospective study
Phase I/II Study of Combination Chemotherapy with S-1 and Cisplatin in Patients with Previously Untreated Metastatic or Recurrent Advanced Gastric Cancer (AGC)
Salvage Chemotherapy with Irinotecan, 5-fluorouracil and Leucovorin in Patients with Advanced Gastric Cancer
No Relationship between C-kit Mutation and Response to Imatinib in Korean Patients with Metastatic Gastrointestinal Stromal Tumor
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach:Report of Three Cases
Phase I/II study of combination chemotherapy with S-1 and cisplatin in patients with previously untreated metastatic or recurrent gastric cancer
Clinical Outcome in Gastrointestinal Stromal Tumor Patients who Interrupted Imatinib after Achieving Stable Disease or Better Response
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin in patients with advanced gastric cancer
No relationship between c-kit mutation and response to imatinib in Korean patients with metastatic gastrointestinal stromal tumor
Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer
Efficacy and safery study of epirubicn and etoposide combination chemotherapy in advanced hepatocellular carcinoma
Efficacy and Safety Study of Epirubicin and Etoposide Combination Chemotherapy in Advanced Hepatocellular Carcinoma
Improved survival of metastatic GIST patients in post-imatinib era compared to those in pre-imatinib era